Welcome to our dedicated page for LeMaitre Vascular news (Ticker: LMAT), a resource for investors and traders seeking the latest updates and insights on LeMaitre Vascular stock.
LeMaitre Vascular, Inc. (Nasdaq: LMAT) is a leading provider of medical devices and implants for the treatment of peripheral vascular disease, a condition that affects over 200 million people globally. The company develops, manufactures, and markets disposable and implantable vascular devices aimed at addressing the needs of vascular surgeons. LeMaitre Vascular offers a diversified product portfolio that includes angioscopes, balloon catheters, carotid shunts, phlebectomy devices, vascular grafts, vascular patches, and vessel closure systems.
Headquartered in Burlington, Massachusetts, LeMaitre's products are utilized during open vascular surgeries, primarily focusing on several anatomical areas such as the carotid, lower extremities, upper extremities, and aorta. The company's lower extremities product line generates the highest revenue, followed by the carotid product line. In recent financial updates, the company reported significant growth in sales across various product categories including bovine patches, valvulotomes, and carotid shunts.
LeMaitre Vascular continues to demonstrate robust financial health. For Q3 2023, the company reported a 21% increase in sales and a 49% rise in operating income, driven by price increases and operational efficiencies. Operating income for Q4 2023 was up 46%, reflecting strong sales growth and improved gross margins. In addition, LeMaitre has a share repurchase program and regularly pays dividends to its shareholders, exemplifying its commitment to shareholder value.
Furthermore, LeMaitre Vascular is focused on expanding its global footprint. Sales in the Americas, EMEA, and APAC regions have shown substantial growth, contributing significantly to the company's revenue. The company also emphasizes compliance with global regulatory requirements, ensuring that its products meet stringent quality standards.
LeMaitre frequently engages with investors through earnings calls, providing transparency about its financial performance and strategic outlook. The company remains committed to innovation and development, constantly working on new projects to enhance its product offerings and address emerging market needs.
For more information about LeMaitre Vascular and its latest updates, visit their official website at www.lemaitre.com.
LeMaitre Vascular (Nasdaq:LMAT) announced its participation in two investor conferences this November. David Roberts, President, will present at the Stifel Virtual Healthcare Conference on November 16, 2020, at 8:00 AM ET. Meanwhile, JJ Pellegrino, Chief Financial Officer, is set to speak at the Canaccord Genuity 2020 Medical Technologies & Diagnostics Forum on November 19, 2020, at 9:30 AM ET. LeMaitre Vascular specializes in devices for treating peripheral vascular disease, serving over 200 million people globally.
LeMaitre Vascular, Inc. (Nasdaq:LMAT) announced its Q3 2020 results with sales reaching $36.4 million, reflecting a 25% increase. Operating income surged 70% to $10.0 million, with a net income of $7.5 million, a 45% rise. The company declared a quarterly dividend of $0.095/share. Growth was driven by acquisitions and recovery in elective surgeries. However, gross margin fell to 62.3% from 69.3% a year prior. Guidance for Q4 anticipates sales between $34.0 million and $38.0 million.
LeMaitre Vascular, Inc. (Nasdaq:LMAT) announced it will release its third quarter 2020 financial results on October 29, 2020, after market close. A conference call is scheduled for 5:00 PM EDT that day to discuss the financial results and the company's outlook. Interested parties can join the call at 844-239-5284 or access the live webcast through their investor relations website.
LeMaitre Vascular specializes in devices for the treatment of peripheral vascular disease, a condition impacting over 200 million people globally.
LeMaitre Vascular (Nasdaq: LMAT) announced its participation in three investor conferences throughout September 2020. JJ Pellegrino, CFO, will engage in the Barrington Research Virtual Fall Investment Conference on September 9, followed by a presentation at the Cantor Virtual Global Healthcare Conference on September 15 at 4:00 PM EDT. Pellegrino will also present at the Sidoti Virtual Investor Conference on September 23 at 10:45 AM EDT. LeMaitre specializes in devices for treating peripheral vascular disease, impacting over 200 million globally.
LeMaitre Vascular, Inc. (Nasdaq: LMAT) announced participation in two upcoming investor conferences in August 2020. CFO JJ Pellegrino will present at the virtual Canaccord Genuity 40th Annual Growth Conference on August 13 at 8:00 AM EDT. Additionally, President David Roberts will attend the virtual 5th Annual Needham Med Tech & Diagnostics 1×1 Conference on August 17. LeMaitre Vascular specializes in devices and services for peripheral vascular disease, which affects over 200 million people globally, offering a diverse range of vascular devices for surgeons.
LeMaitre Vascular, Inc. (LMAT) reported Q2 2020 results, with sales of $24.9 million, a decline of 16% year-over-year. Operating income fell 18% to $4.9 million, while net income decreased by 24% to $3.5 million, resulting in earnings of $0.17 per diluted share, down 25%. Despite a 20% operating margin, sales declined significantly due to the COVID-19 pandemic, particularly in the Americas and Europe. The company announced a quarterly dividend of $0.095 per share and provided limited Q3 guidance, projecting sales between $30.5 million and $34.5 million.
LeMaitre Vascular, Inc. (Nasdaq: LMAT) will release its second quarter 2020 financial results on July 23, 2020, after market close. A conference call is scheduled for 5:00 PM EDT to discuss results, business highlights, and company outlook. LeMaitre offers devices and services for peripheral vascular disease, which affects over 200 million people globally. The company specializes in developing disposable and implantable vascular devices, targeting vascular surgeons with its diverse product portfolio.
LeMaitre Vascular, Inc. (Nasdaq: LMAT) announced the acquisition of Artegraft, Inc. for $90 million, which includes $72.5 million in cash and potential earnouts of $17.5 million. Artegraft, known for its biologic vascular grafts used primarily in hemodialysis patients, generated $15.6 million in trade sales over the last year. This acquisition is expected to enhance LeMaitre's product offerings and profitability, positioning Artegraft as the largest product line in their sales portfolio. The deal will be funded through cash and a $65 million credit facility.
LeMaitre Vascular, Inc. (Nasdaq: LMAT) announced that CFO JJ Pellegrino will speak at the Jefferies Virtual Healthcare Conference on June 4, 2020, at 2:00 PM EDT. LeMaitre Vascular specializes in developing and marketing devices for peripheral vascular disease, which impacts over 200 million individuals globally. The company offers a range of disposable and implantable vascular devices for use by vascular surgeons. More details can be found on their website at www.lemaitre.com.
LeMaitre Vascular, listed on Nasdaq under the symbol LMAT, will be presented by President David Roberts at the UBS Virtual Global Healthcare Conference on May 20, 2020, at 8:20 AM EDT. The company specializes in developing and marketing devices for peripheral vascular disease, impacting over 200 million people globally. Their extensive product range focuses on disposable and implantable vascular devices tailored for vascular surgeons, enhancing treatment options for patients.
FAQ
What is the current stock price of LeMaitre Vascular (LMAT)?
What is the market cap of LeMaitre Vascular (LMAT)?
What products does LeMaitre Vascular offer?
Where is LeMaitre Vascular headquartered?
In which medical areas are LeMaitre's products primarily used?
What was the company's financial performance in Q3 2023?
How does LeMaitre Vascular engage with its investors?
What regions contribute significantly to LeMaitre's revenue?
Does LeMaitre Vascular pay dividends to its shareholders?
What recent financial achievements has LeMaitre Vascular reported?
How does LeMaitre ensure the quality of its products?
Where can I find more information about LeMaitre Vascular?
